RPG Life Sciences (RPGLIFE) Q3 25/26 earnings summary

Executive summary

• Integrated pharmaceutical company with domestic and international presence, focusing on branded formulations, generics, and APIs.

• Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, were approved by the Board on January 27, 2026.

• Business transformation initiatives include building mega brands, expanding global play, and sustainable operations with significant capex infusion.

• Strong product portfolio in chronic and specialty therapies, with leadership in immunosuppressants and presence in 50+ markets.

• Results reviewed by statutory auditors, with no material misstatements identified.

Financial highlights

• Revenue from operations for 9M FY26 grew 4.0% year-over-year to ₹530.6 crore (₹53,063 lakhs).

• Q3 FY26 revenue was ₹180.0 crore (₹18,003 lakhs), up 4.2% year-over-year.

• EBITDA declined 10.1% year-over-year to ₹127.4 crore, with margin dropping from 27.8% to 24.0%.

• PAT (excluding exceptional items) fell 11.3% year-over-year to ₹82.6 crore, with margin at 15.6%.

• Net profit for the quarter was ₹2,213 lakhs, compared to ₹3,493 lakhs in the prior year quarter.

Outlook and guidance

• Strategic focus on portfolio development, mega-brand building, and expanding API business.

• Ongoing digital initiatives and M&A evaluations to drive efficiency and growth.

• Continued investment in capacity expansion and talent development.

• The transfer of the API division to a wholly owned subsidiary is expected to streamline business structure and improve operational focus, with completion targeted by February 2026.